HFpEF have diabetes, and this proportion is expected to increase. Diabetes has adverse prognostic significance in patients with HFpEF, likely because of overlapping pathophysiological sequelae, including neurohormonal activation, inflammation, and impaired skeletal muscle function. Coronary artery disease is c...
No history of diabetes 60 points: 100–125 (5.7%–6.4%) 20 points: diabetes (8.0%–8.9%) 0 points: diabetes (≥10.0%) AHA indicates American Heart Association; CVH, cardiovascular health; DASH, Dietary Approaches to Stop Hypertension; HbA1c, hemoglobin A1c; HDL, high- density lipoprotein; ...
2023年7月美国心脏协会(AHA)、美国心脏病学会(ACC)等6个学术组织联合发布了《2023 AHA/ACC/ACCP/ASPC/NLA/PCNA慢性冠状动脉疾病患者管理指南》,该指南提供了一种以循证为基础和以患者为中心的方法综合管理慢性冠状动脉疾病患者,内容涉及慢性冠状动脉疾病的流行病学,以及对患者的评估、诊断与风险分层、治疗、特殊人群...
guidelines;AmericanHeartAssociation [1] 心血管疾病是全球最主要的死亡原因,基于我益前提下改善心血管健康。本文对2023CCD指南要点 国人口老龄化加速,居民不健康的生活方式,具备心血进行解读,以期为临床实践,特别是中国分级诊疗制度 管疾病危险因素的人群庞大,我国心血管疾病发病率与下的基层医疗提供循证指导,为提供高质...
To improve outcomes, the AHA/ACC recommends use of sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for select CCD patient groups, including those without diabetes. The AHA/ACC considers shorter durations of dual antiplatelet therapy as safe ...
The official AHA publication for ICD-10-CM and ICD-10-PCS coding guidelines and advice Current newsletters added each quarter Full Archives - over 3100 articles ALL years/issues back to 1984 organized by year and issue Includes ICD-10-CM/PCS Articles since 2013 Fully searchable through Find-A...
Sotagliflozin in patients with diabetes and recent worsening heart failure[J]. N Engl J Med, 2021, 384(2):117-128. https://doi.org/10.1056/NEJMoa2030183 http://www.nejm.org/doi/10.1056/NEJMoa2030183 本文引用 [1] [13] ANKER S D, BUTLER J, FILIPPATOS G, et al. Empagli-floz...
Little is known about statin underutilization among diabetes mellitus patients cared for in community health centers, which tend to serve socioeconomically disadvantaged populations. Implications of the American College of Cardiology/American Heart Association (ACC/AHA) guidelines on preexisting gaps in stat...
10:02 - SELECT: Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes We value your opinion! Share your feedback by commenting on this page or sending us an email at info@radcliffe-group.com.Overview...
Two posted presented at the American Heart Association’s 2024 Scientific Sessions explored empagliflozin among patients with type 2 diabetes and cardiovascular risk. The sodium-glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin could help improve clinical outcomes in patients who hav...